Patents by Inventor Jason M. Cox

Jason M. Cox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS
    Publication number: 20240246932
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: May 2, 2022
    Publication date: July 25, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Jason M. Cox, Michael J. Kelly, III, Mark Eric Layton, Hong Liu, Jian Liu, Akshay A. Shah, Michael D. VanHeyst
  • INHIBITORS OF RAF KINASES
    Publication number: 20240182467
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: September 29, 2023
    Publication date: June 6, 2024
    Inventors: Toufike KANOUNI, Jason M. COX, John TYHONAS, Robert S. KANIA, Subhas J. CHAKRAVORTY, Young K. CHEN
  • INHIBITORS OF MET KINASE
    Publication number: 20240067626
    Abstract: Provided herein are inhibitors of MET receptor tyrosine kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MET kinase inhibitory compounds for the treatment of disease.
    Type: Application
    Filed: June 26, 2023
    Publication date: February 29, 2024
    Inventors: Xiaohu S. OUYANG, Toufike KANOUNI, John S. TYHONAS, Jason M. COX, Robert S. KANIA
  • INHIBITORS OF MEK KINASE
    Publication number: 20230416286
    Abstract: Provided herein are inhibitors of MEK kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MEK kinase inhibitory compounds for the treatment of disease.
    Type: Application
    Filed: June 15, 2023
    Publication date: December 28, 2023
    Inventors: Toufike KANOUNI, Robert S. KANIA, Jason M. COX
  • Inhibtors of Raf kinases
    Patent number: 11814384
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: November 14, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Jason M. Cox, John Tyhonas, Robert S. Kania, Subhas J. Chakravorty, Young K. Chen
  • 2-oxoimidazolidine-4-carboxamides as NA1.8 inhibitors
    Patent number: 11802122
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Grant
    Filed: June 15, 2021
    Date of Patent: October 31, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Christopher James Bungard, Christopher S. Burgey, Jason M. Cox, Michael J. Kelly, III, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Akshay A. Shah, Michael David VanHeyst, Zhe Wu
  • Inhibitors of MEK kinase
    Patent number: 11780862
    Abstract: Provided herein are inhibitors of MEK kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MEK kinase inhibitory compounds for the treatment of disease.
    Type: Grant
    Filed: February 27, 2023
    Date of Patent: October 10, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Robert S. Kania, Jason M. Cox
  • 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS
    Publication number: 20230312528
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: June 5, 2023
    Publication date: October 5, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Christopher James Bungard, Christopher S. Burgey, Jason M. Cox, Michael J. Kelly, III, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Akshay A. Shah, Michael David VanHeyst, Zhe Wu
  • INHIBITORS OF RAF KINASES
    Publication number: 20230303566
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: February 3, 2023
    Publication date: September 28, 2023
    Inventors: Toufike KANOUNI, Jason M. COX, John TYHONAS, Robert S. KANIA, Subhas J. CHAKRAVORTY, Young K. CHEN
  • Inhibitors of MET kinase
    Patent number: 11753395
    Abstract: Provided herein are inhibitors of MET receptor tyrosine kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MET kinase inhibitory compounds for the treatment of disease.
    Type: Grant
    Filed: December 14, 2022
    Date of Patent: September 12, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Xiaohu S. Ouyang, Toufike Kanouni, John S. Tyhonas, Jason M. Cox, Robert S. Kania
  • INHIBITORS OF MEK KINASE
    Publication number: 20230279033
    Abstract: Provided herein are inhibitors of MEK kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MEK kinase inhibitory compounds for the treatment of disease.
    Type: Application
    Filed: February 27, 2023
    Publication date: September 7, 2023
    Inventors: Toufike KANOUNI, Robert S. KANIA, Jason M. COX
  • INHIBITORS OF MET KINASE
    Publication number: 20230219929
    Abstract: Provided herein are inhibitors of MET receptor tyrosine kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MET kinase inhibitory compounds for the treatment of disease.
    Type: Application
    Filed: December 14, 2022
    Publication date: July 13, 2023
    Inventors: Xiaohu S. OUYANG, Toufike KANOUNI, John S. TYHONAS, Jason M. COX, Robert S. KANIA
  • INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
    Publication number: 20230078839
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: March 23, 2022
    Publication date: March 16, 2023
    Inventors: Stephen W. KALDOR, John TYHONAS, Eric A. MURPHY, Toufike KANOUNI, Lee D. ARNOLD, Robert KANIA, Jason M. COX
  • CYCLOALKYL 3-OXOPIPERAZINE CARBOXAMIDES AND CYCLOHETEROALKYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS
    Publication number: 20220380338
    Abstract: Novel compounds of structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of Formula I may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: May 5, 2022
    Publication date: December 1, 2022
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Jason M. Cox, Michael J. Kelly, III, Mark Eric Layton, Hong Liu, Jian Liu, Akshay A. Shah, Michael D. VanHeyst
  • 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS
    Publication number: 20220289710
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: May 24, 2022
    Publication date: September 15, 2022
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L.G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
  • 2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors
    Patent number: 11377438
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: July 5, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L. G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
  • Inhibitors of fibroblast growth factor receptor kinases
    Patent number: 11345681
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: May 31, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, John Tyhonas, Eric A. Murphy, Toufike Kanouni, Lee D. Arnold, Robert Kania, Jason M. Cox
  • PYRAZOLOPYRIMIDINE PDE9 INHIBITORS
    Publication number: 20220017526
    Abstract: The present invention is directed to amino and alkyl pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 20, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashok Arasappan, Jason M. Cox, John S. Debenham, Zhe Feng, Zhuyan Guo, Dongfang Meng
  • CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS
    Publication number: 20220017525
    Abstract: The present invention is directed to cyclobutyl pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 20, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashok Arasappan, Jason M. Cox, John S. Debenham, Zhuyan Guo, Zhong Lai, Dongfang Meng
  • 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS
    Publication number: 20220000844
    Abstract: Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.
    Type: Application
    Filed: December 2, 2019
    Publication date: January 6, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Bungard, Helen Y. Chen, Jason M. Cox, Liangqin Guo, Michael J. Kelly, III, Ronald M. Kim, Mark E. Layton, Hong Liu, Jian Liu, Mehul F. Patel, James J. Perkins, Deping Wang, Walter Won, Younong Yu, Ting Zhang